Long-term virologic response and genotypic resistance mutations in HIV-1 infected kenyan children on combination antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 62, Issue 3, 2013, Pages 267-274

  Wamalwa, Dalton C ^a   Lehman, Dara A ^b   Benki Nugent, Sarah ^c   Gasper, Melanie A ^b,c   Gichohi, Richard ^a   Maleche Obimbo, Elizabeth ^a   Farquhar, Carey ^c   John Stewart, Grace C ^c   Overbaugh, Julie ^b  

^a UNIVERSITY OF NAIROBI   (Kenya)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antiretroviral; Children; HIV; Kenya; Resistance; Viral failure

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS STAVUDINE; VIRUS RNA;

AGE; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CHILD; CHILDHOOD DISEASE; COMBINATION CHEMOTHERAPY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KENYA; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SEQUENCE ANALYSIS; SEX DIFFERENCE; VERTICAL TRANSMISSION; VIREMIA; VIRUS LOAD;

EID: 85027944736     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31827b4ac8     Document Type: Article

References (33)

1. Brady MT, Oleske JM, Williams PL, et al. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. J Acquir Immune Defic Syndr. 2010;53:86-94.
2. Patel K, Hernán MA, Williams PL, et al. Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting. Clin Infect Dis. 2008;46:1751-1760.
3. World Health Organization. Antiretroviral therapy of HIV infection in infants and children: towards universal access. Recommendations for a public health approach, 2010 revision. 1-206. Available at: http://www.who.int/hiv/pub/ paediatric/infants2010/en/index.html Accessed August 2011.
4. Ciaranello AL, Chang Y, Margulis AV, et al. Effectiveness of pediatric antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. Clin Infect Dis. 2009;49:1915-1927.
5. Sutcliffe CG, van Dijk JH, Bolton C, et al. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis. 2008;8:477-489.
6. Barth R, Tempelman H, Smelt E, et al. Long-term outcome of children receiving antiretroviral treatment in rural South Africa. Pediatr Infect Dis J. 2011;30:52-56.
7. Rouet F, Fassinou P, Inwoley A, et al. Long-term survival and immunovirological response of African HIV-1-infected children to highly active antiretroviral therapy regimens. AIDS. 2006;20:2315-2319.
8. Kamya MR, Mayanja-Kizza H, Kambugu A, et al. Predictors of longterm viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;46:187-193.
9. Lwembe R, Ochieng W, Panikulam A, et al. Anti-retroviral drug resistance- associated mutations among non-subtype B HIV-1-infected Kenyan children with treatment failure. J Med Virol 2007;79:865-872.
10. Kantor R, Diero L, Delong A, et al. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis. 2009;49:454-462.
11. van Oosterhout JJ, Brown L, Weigel R, et al. Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria. Trop Med Int Health. 2009;14:856-861.
12. Keiser O, Tweya H, Boulle A, et al, and ART-LINC of IeDEA Study Group. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS. 2009;23:1867-1874.
13. The PENPACT-1 (PENTA 9/PACTG 390) Study Team. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIVinfected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis. 2011;11:273-283.
14. Wamalwa DC, Farquhar C, Obimbo EM, et al. Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children. J Acquir Immune Defic Syndr. 2007;45:311-317.
15. Wamalwa DC, Obimbo EM, Farquhar C, et al. Predictors of mortality in HIV-1 infected children on antiretroviral therapy in Kenya: a prospective cohort. BMC Pediatr. 2010;10:33.
16. Kenya Ministry of Health. National AIDS and STI Control Program, Guidelines for Antiretroviral Therapy in Kenya. 4th ed. National AIDS/STI Control Program (NASCOP); Kenya. 2011:1-203. Available at: http://www.nascop.or. ke/art/Accessed April 2011.
17. Emery S, Bodrug S, Richardson BA, et al. Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. J Clin Microbiol. 2000;38:2688-2695.
18. Lehman DA, Chung MH, Mabuka JM, et al. Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission. J Acquir Immune Defic Syndr. 2009;51:522-529.
19. Stanford University HIV drug resistance database. Available at: http://hivdb.stanford.edu/Accessed August 2011.
20. van Dijk JH, Sutcliffe CG, Munsanje B, et al. HIV-infected children in rural Zambia achieve good immunologic and virologic outcomes two years after initiating antiretroviral therapy. PLoS ONE. 2011;6(4): e19006.
21. Frange P, Briand N, Avettand-fenoel V, et al. Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure. Pediatr Infect Dis J. 2011;30:684-688.
22. Ngeno B, Wamalwa DC, Nduati R. Comparison of self-report and pharmacy records as measures of adherence to antiretroviral therapy in HIV-1 infected children in Kneyatta National Hospital. Presented at: 5th IAS Conference on HIV Pathogenesis and Treatment, July 19-22, 2009: Cape Town, South Africa.
23. Adjé-Touré C, Hanson DL, Talla-Nzussouo N, et al. Virologic and immunologic response to antiretroviral therapy and predictors of HIV type 1 drug resistance in children receiving treatment in Abidjan, Côte d'Ivoire. AIDS Res Hum Retroviruses. 2008;24:911-917.
24. Holguín A, Erazo K, Escobar G, et al. Drug resistance prevalence in human immunodeficiency virus type 1 infected pediatric populations in Honduras and El Salvador during 1989-2009. Pediatr Infect Dis J. 2011; 30:E82-E87.
25. Reynolds SJ, Kityo C, Mbamanya F, et al. Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda. Antivir Ther. 2009;14:293-297.
26. Naeger LK, Margot NA, Miller MD. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine- associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication. Antivir Ther. 2001;6:115-126.
27. Barth RE, Wensing AM, Tempelman H, et al. Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa. AIDS. 2008;22:2210-2212.
28. Orrell C, Harling G, Lawn SD, et al. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther. 2007;12:83-88.
29. Wilson D, Keiluhu AK, Kogrum S, et al. HIV-1 viral load monitoring: an opportunity to reinforce treatment adherence in a resource-limited setting in Thailand. Trans R Soc Trop Med Hyg. 2009;103:601-606.
30. Petersen ML, van der Laan MJ, Napravnik S, et al. Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS. 2008;22:2097-2106.
31. Oliveira R, Krauss M, Essama-Bibi S, et al. Viral load predictts new world health organization stage 3 and 4 events in HIV-infected children receiving highly active antiretroviral therapy, independent of CD4 T lymphocyte value. Clin Infect Dis. 2010;51:1325-1333.
32. Kosalaraksa P, Ananworanich J, Puthanakit T, et al. Lopinavir/ritonavir Monotherapy in HIV-infected Children; week 144 results. Abstract #962. Presented at: 19th Conference on Retroviruses and Opportunistic Infections; March 5-8, 2012; Seattle, WA.
33. Neth O, Falcon-Neyra L, Ruiz-Valderas R, et al. Simplified human immunodeficiency virus maintenance therapy in virologically suppressed children with ritonavir-boosted protease inhibitor monotherapy. Pediatr Infect Dis J. 2011;30:917.